Boehringer Ingelheim's Phase III spesolimab trial leads a small PG pipeline shaped by IL-36, IL-23/IL-17 and complement research, as InflaRx's vilobelimab program stalls.Dublin, Oct. (GLOBE NEWSWIRE) ...
Asthma pipeline highlights novel biologics and small molecules, clinical-stage progress, unmet needs, collaborations, licensing and acquisition activity.Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- ...
A first impression of a patient’s skin can help guide the differential diagnosis and provide clues to the underlying diseases associated with cutaneous changes. Some findings may serve as early ...
Pyoderma gangrenosum recurred in more than a third of patients after complete healing in a study, and cumulative recurrence risk reached 41% at 5 years. Recurrence occurred in 41 (35%) of 116 ...
Post-surgical pyoderma gangrenosum was successfully managed following bilateral mastectomy after clinical recognition prompted a shift to immunosuppressive therapy, avoiding further surgical ...
The study pointed to TNF blockade as a potential therapeutic option for patients with OTULIN-related pyoderma gangrenosum. The investigators noted that one patient, whose painful skin sores were ...
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that presents with rapidly developing, painful skin ulcers hallmarked by undermined borders and peripheral erythema. Epidemiological studies ...
Previous analyses of mortality data from the Centers for Disease Control and Prevention (CDC) showed that the leading cause of death among children and adolescents (defined as persons 1 to 19 years of ...
aOregon Health and Science University, Department of the School of Medicine, Portland, OR, United States of America bOregon Health and Science University, Department of Dermatology, Portland, OR, ...
JENA, Germany, March 18, 2026 (GLOBE NEWSWIRE)-- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...
InflaRx announced the results of post-hoc analyses from a terminated Phase 3 trial investigating vilobelimab for ulcerative pyoderma gangrenosum (PG), which was halted earlier this year due to an ...
In 2025, the pyoderma gangrenosum therapeutics market was valued at USD 402.3 million. Based on Future Market Insights' analysis, demand for pyoderma gangrenosum therapeutics is estimated to grow to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results